A Phase 1 Randomized, Single Center, Double-Blind, Placebo-Controlled, Dose-Response and Open-Label or Single Blind Booster Study to Evaluate the Safety and Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
Latest Information Update: 28 Oct 2024
At a glance
- Drugs RVSV Nipah vaccine-Public Health Vaccines (Primary)
- Indications Nipah virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Public Health Vaccine
Most Recent Events
- 30 Jan 2024 Status changed from active, no longer recruiting to completed.
- 25 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 04 Nov 2023 Planned End Date changed from 1 Jan 2024 to 1 Mar 2024.